Real-world outcomes with lisocabtagene maraleucel in R/R LBCL

The Lymphoma Hub was pleased to speak to Patrick Connor Johnson, Massachusetts General Hospital, Boston, US. We asked about real-world outcomes with lisocabtagene maraleucel (liso-cel) for the treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

In this interview, Johnson highlights the importance of understanding how clinical trial efficacy and safety data translate to the real-world setting. He goes on to share real-world outcomes published by Crombie et al.¹ for patients with R/R LBCL treated with liso-cel in the US who were followed in the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy Registry between February 2021 and November 2022. Johnson covers the key efficacy and safety from the analysis, and emphasizes that that the real-world data mirrors that seen in the published pivotal clinical trials of liso-cel. He concludes that the data are encouraging, supporting the application of liso-cel as a treatment for patients with R/R LBCL in the real world.

During the interview, Johnson shared the following key points:

• Over 300 patients (323) with LBCL who received commercial liso-cel were included in this real-world analysis. 
• The median age of patients was 70 years, most patients had diffuse LBCL not otherwise specified, and the median number of prior lines of systemic therapy was 3.
• At a median follow-up of 7.4 months, the overall response rate was 79%, with a complete response rate of 65%.
• The 6-month estimated progression-free survival and overall survival rates were 64% and 82%, respectively.
• The proportions of patients experiencing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were 52% and 30%, respectively, which is similar to the proportions observed in the pivotal clinical trials of liso-cel. 
• The real-world data approximate that seen in the pivotal studies of liso-cel, providing encouraging efficacy and safety data supporting the use of liso-cel in the real-world setting. 

This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.